Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NFE2L2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NFE2L2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NFE2L2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NFE2L2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NFE2L2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NFE2L2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NFE2L2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NFE2L2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NFE2L2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003497632 | Oral cavity | NEOLP | response to endoplasmic reticulum stress | 56/2005 | 256/18723 | 1.39e-07 | 4.84e-06 | 56 |
GO:003461231 | Oral cavity | NEOLP | response to tumor necrosis factor | 55/2005 | 253/18723 | 2.23e-07 | 7.28e-06 | 55 |
GO:007048232 | Oral cavity | NEOLP | response to oxygen levels | 69/2005 | 347/18723 | 2.66e-07 | 8.54e-06 | 69 |
GO:000166632 | Oral cavity | NEOLP | response to hypoxia | 63/2005 | 307/18723 | 2.75e-07 | 8.78e-06 | 63 |
GO:000963633 | Oral cavity | NEOLP | response to toxic substance | 56/2005 | 262/18723 | 3.13e-07 | 9.85e-06 | 56 |
GO:199074832 | Oral cavity | NEOLP | cellular detoxification | 32/2005 | 116/18723 | 3.30e-07 | 1.03e-05 | 32 |
GO:003629332 | Oral cavity | NEOLP | response to decreased oxygen levels | 65/2005 | 322/18723 | 3.34e-07 | 1.04e-05 | 65 |
GO:007137531 | Oral cavity | NEOLP | cellular response to peptide hormone stimulus | 60/2005 | 290/18723 | 3.92e-07 | 1.19e-05 | 60 |
GO:009723732 | Oral cavity | NEOLP | cellular response to toxic substance | 33/2005 | 124/18723 | 5.39e-07 | 1.61e-05 | 33 |
GO:007135631 | Oral cavity | NEOLP | cellular response to tumor necrosis factor | 50/2005 | 229/18723 | 6.79e-07 | 1.93e-05 | 50 |
GO:003425033 | Oral cavity | NEOLP | positive regulation of cellular amide metabolic process | 39/2005 | 162/18723 | 8.79e-07 | 2.37e-05 | 39 |
GO:005127115 | Oral cavity | NEOLP | negative regulation of cellular component movement | 70/2005 | 367/18723 | 1.10e-06 | 2.90e-05 | 70 |
GO:004362032 | Oral cavity | NEOLP | regulation of DNA-templated transcription in response to stress | 19/2005 | 53/18723 | 1.11e-06 | 2.91e-05 | 19 |
GO:006104123 | Oral cavity | NEOLP | regulation of wound healing | 34/2005 | 134/18723 | 1.21e-06 | 3.13e-05 | 34 |
GO:003596632 | Oral cavity | NEOLP | response to topologically incorrect protein | 38/2005 | 159/18723 | 1.46e-06 | 3.68e-05 | 38 |
GO:005081722 | Oral cavity | NEOLP | coagulation | 48/2005 | 222/18723 | 1.51e-06 | 3.77e-05 | 48 |
GO:003243632 | Oral cavity | NEOLP | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 26/2005 | 90/18723 | 1.58e-06 | 3.89e-05 | 26 |
GO:200006032 | Oral cavity | NEOLP | positive regulation of ubiquitin-dependent protein catabolic process | 29/2005 | 107/18723 | 1.72e-06 | 4.19e-05 | 29 |
GO:004343431 | Oral cavity | NEOLP | response to peptide hormone | 76/2005 | 414/18723 | 1.79e-06 | 4.33e-05 | 76 |
GO:000759621 | Oral cavity | NEOLP | blood coagulation | 47/2005 | 217/18723 | 1.84e-06 | 4.44e-05 | 47 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0522510 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa04141110 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0522513 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa0501244 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
hsa0520844 | Cervix | N_HPV | Chemical carcinogenesis - reactive oxygen species | 32/349 | 223/8465 | 4.82e-10 | 1.87e-08 | 1.47e-08 | 32 |
hsa0541845 | Cervix | N_HPV | Fluid shear stress and atherosclerosis | 20/349 | 139/8465 | 9.29e-07 | 1.41e-05 | 1.10e-05 | 20 |
hsa0414144 | Cervix | N_HPV | Protein processing in endoplasmic reticulum | 21/349 | 174/8465 | 8.84e-06 | 1.09e-04 | 8.55e-05 | 21 |
hsa0541745 | Cervix | N_HPV | Lipid and atherosclerosis | 22/349 | 215/8465 | 7.28e-05 | 7.92e-04 | 6.19e-04 | 22 |
hsa0501254 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
hsa0520854 | Cervix | N_HPV | Chemical carcinogenesis - reactive oxygen species | 32/349 | 223/8465 | 4.82e-10 | 1.87e-08 | 1.47e-08 | 32 |
hsa0541855 | Cervix | N_HPV | Fluid shear stress and atherosclerosis | 20/349 | 139/8465 | 9.29e-07 | 1.41e-05 | 1.10e-05 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NFE2L2 | SNV | Missense_Mutation | | c.242N>A | p.Gly81Asp | p.G81D | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
NFE2L2 | SNV | Missense_Mutation | | c.959N>G | p.Ser320Cys | p.S320C | Q16236 | protein_coding | tolerated(0.19) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NFE2L2 | SNV | Missense_Mutation | | c.371C>G | p.Ala124Gly | p.A124G | Q16236 | protein_coding | deleterious(0.03) | benign(0.02) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
NFE2L2 | insertion | Frame_Shift_Ins | novel | c.1128_1129insTT | p.Glu377LeufsTer6 | p.E377Lfs*6 | Q16236 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
NFE2L2 | insertion | Frame_Shift_Ins | novel | c.1126_1127insTTGTGGTTATAATTTCCCTGATTTGCCATGAGTTTGAACATCTTCCA | p.Ser376PhefsTer22 | p.S376Ffs*22 | Q16236 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
NFE2L2 | deletion | Frame_Shift_Del | novel | c.129delN | p.Glu45SerfsTer32 | p.E45Sfs*32 | Q16236 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
NFE2L2 | SNV | Missense_Mutation | novel | c.594G>T | p.Gln198His | p.Q198H | Q16236 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NFE2L2 | SNV | Missense_Mutation | | c.1138G>C | p.Glu380Gln | p.E380Q | Q16236 | protein_coding | deleterious(0.01) | possibly_damaging(0.522) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NFE2L2 | SNV | Missense_Mutation | | c.85G>C | p.Asp29His | p.D29H | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
NFE2L2 | SNV | Missense_Mutation | | c.1544N>C | p.Arg515Thr | p.R515T | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | ALDICARB | ALDICARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | 3,3'-DIMETHOXYBENZIDINE | CHEMBL398363 | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | LOTEPREDNOL ETABONATE | LOTEPREDNOL ETABONATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | BECLOMETHASONE DIPROPIONATE | BECLOMETHASONE DIPROPIONATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PHENOXYCARB | PHENOXYCARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | METHIOCARB | METHIOCARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | JNJ-1661010 | CHEMBL460273 | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | NALED | NALED | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | MORNIFLUMATE | MORNIFLUMATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | RHEIN | RHEIN | |